Summary

Japan Ophthalmic Drugs and Devices Market Research Report By Product (Drugs, Devices) and By Treatment (Eye Infections, Allergic Conjunctivitis, Dry Eyes Syndrome, Red Eyes, Inflammation, Others) - Growth & Industry Forecast 2025 To 2035

Market Summary:
As per analysis, the Japan ophthalmic drugs devices market is projected to grow from USD 2.91 Billion in 2025 to USD 4.73 Billion by 2035, exhibiting a compound annual growth rate (CAGR) of 5.14% during the forecast period (2025 - 2035).

Market Drivers:
The growing awareness of eye health among the Japanese population is a pivotal driver for the japan ophthalmic drugs devices market. Public health campaigns and educational initiatives have been instrumental in informing citizens about the importance of regular eye check-ups and early detection of eye diseases. As a result, more individuals are seeking preventive care and treatment options, leading to increased demand for ophthalmic drugs and devices. Furthermore, the rise of digital technology and screen usage has heightened concerns regarding eye strain and related disorders, prompting consumers to invest in eye care solutions. This heightened awareness is expected to continue influencing the market positively, as more people prioritize their eye health in the coming years. The aging population in Japan is a significant driver for the japan ophthalmic drugs devices market. As the demographic shifts towards an older age group, the prevalence of age-related eye disorders, such as cataracts and macular degeneration, is expected to rise.

Market Segment Analysis:
In the Japan Ophthalmic Drugs Devices Market, the application segment is primarily dominated by glaucoma treatments, which hold the largest share of the market. This is largely attributable to the high prevalence of glaucoma in the Japanese population, driving significant investment in the development and marketing of effective therapies. Other significant applications include cataracts and retinal disorders, although they account for a smaller percentage of the overall market compared to glaucoma. Cataract: Dominant vs. Retinal Disorders: Emerging Cataract treatments remain a dominant application within the Japan ophthalmic drugs devices market due to the aging population and the high incidence of cataract surgeries performed annually. These treatments are well-established, widely accepted, and supported by robust clinical data. In contrast, retinal disorders are categorized as an emerging segment, showing potential for rapid growth as awareness increases and new therapies are developed.

Regional Analysis:
The Japan Ophthalmic Drugs Devices Market is currently experiencing a dynamic evolution, driven by advancements in technology and an increasing prevalence of eye-related disorders. The aging population in Japan is contributing to a higher demand for effective treatment options, as conditions such as cataracts, glaucoma, and age-related macular degeneration become more common. Furthermore, the government is actively promoting research and development initiatives, which appear to foster innovation in ophthalmic therapies and devices. This environment encourages collaboration between healthcare providers and manufacturers, potentially leading to enhanced patient outcomes and improved quality of life. In addition, the regulatory landscape in Japan is evolving to accommodate new technologies and treatment modalities.

Major Players:
The following companies are key participants in the Japan Ophthalmic Drugs Devices Market, playing a crucial role in market development through technological innovation, strategic partnerships, and competitive product offerings.

ページTOPに戻る

Table of Contents

TABLE OF CONTENT
1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
EXECUTIVE SUMMARY
Market Overview
Key Findings
Market Segmentation
Competitive Landscape
Challenges and Opportunities
Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
MARKET INTRODUCTION
Definition
Scope of the study
Research Objective
Assumption
Limitations
RESEARCH METHODOLOGY
Overview
Data Mining
Secondary Research
Primary Research
Primary Interviews and Information Gathering Process
Breakdown of Primary Respondents
Forecasting Model
Market Size Estimation
Bottom-Up Approach
Top-Down Approach
Data Triangulation
Validation
3 SECTION III: QUALITATIVE ANALYSIS
MARKET DYNAMICS
Overview
Drivers
Restraints
Opportunities
MARKET FACTOR ANALYSIS
Value chain Analysis
Porter's Five Forces Analysis
Bargaining Power of Suppliers
Bargaining Power of Buyers
Threat of New Entrants
Threat of Substitutes
Intensity of Rivalry
COVID-19 Impact Analysis
Market Impact Analysis
Regional Impact
Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
Japan Healthcare Market SegmentationHealthcare By Application (USD Billion, 2025-2035)GlaucomaInfectionInflammationDry EyeCataractHealthcare By Device Type (USD Billion, 2025-2035)Surgical InstrumentsDiagnostic EquipmentDrug Delivery DevicesContact LensesIntraocular LensesHealthcare By Formulation Type (USD Billion, 2025-2035)Ophthalmic SolutionsOphthalmic SuspensionsOphthalmic OintmentsOphthalmic GelsOphthalmic Inserts SECTION V: COMPETITIVE ANALYSIS
Competitive Landscape
Overview
Competitive Analysis
Market share Analysis
Major Growth Strategy in the Japan Ophthalmic Drugs and Devices Market
Competitive Benchmarking
Leading Players in Terms of Number of Developments in the Japan Ophthalmic Drugs and Devices Market
Key developments and growth strategies
New Product Launch/Service Deployment
Merger & Acquisitions
Joint Ventures
Major Players Financial Matrix
Sales and Operating Income
Major Players R&D Expenditure. 2023
Company Profiles
Fujirebi
-
Financial Overview
Products Offered
Key Developments
SWOT Analysis
Key Strategies
Sysmex Corporation
Financial Overview
Products Offered
Key Developments
SWOT Analysis
Key Strategies
Astellas Pharma Inc.
Financial Overview
Products Offered
Key Developments
SWOT Analysis
Key Strategies
Takara Bi
Inc.
Financial Overview
Products Offered
Key Developments
SWOT Analysis
Key Strategies
Mitsubishi Chemical Corporation
Financial Overview
Products Offered
Key Developments
SWOT Analysis
Key Strategies
Hiroshima University
Financial Overview
Products Offered
Key Developments
SWOT Analysis
Key Strategies
Kyot
University
Financial Overview
Products Offered
Key Developments
SWOT Analysis
Key Strategies
Osaka University
Financial Overview
Products Offered
Key Developments
SWOT Analysis
Key Strategies
Appendix
References
Related Reports

COMPANIES MENTIONED
Santen Pharmaceutical Co , Otsuka Pharmaceutical Co , Alcon Japan Ltd , Kowa Company Ltd , Nippon Chemiphar Co Ltd , Senju Pharmaceutical Co Ltd , Mochida Pharmaceutical Co Ltd , Hoya Corporation

ページTOPに戻る

List of Tables/Graphs

LIST OF FIGURES
FIGURE 1 MARKET SYNOPSIS
FIGURE 2 JAPAN OPHTHALMIC DRUGS AND DEVICES MARKET ANALYSIS BY PRODUCT
FIGURE 3 JAPAN OPHTHALMIC DRUGS AND DEVICES MARKET ANALYSIS BY TREATMENT
FIGURE 4 KEY BUYING CRITERIA OF JAPAN OPHTHALMIC DRUGS AND DEVICES MARKET
FIGURE 5 RESEARCH PROCESS OF MRFR
FIGURE 6 DRO ANALYSIS OF JAPAN OPHTHALMIC DRUGS AND DEVICES MARKET
FIGURE 7 DRIVERS IMPACT ANALYSIS: JAPAN OPHTHALMIC DRUGS AND DEVICES MARKET
FIGURE 8 RESTRAINTS IMPACT ANALYSIS: JAPAN OPHTHALMIC DRUGS AND DEVICES MARKET
FIGURE 9 SUPPLY / VALUE CHAIN: JAPAN OPHTHALMIC DRUGS AND DEVICES MARKET
FIGURE 10 JAPAN OPHTHALMIC DRUGS AND DEVICES MARKET, BY PRODUCT, 2024 (% SHARE)
FIGURE 11 JAPAN OPHTHALMIC DRUGS AND DEVICES MARKET, BY PRODUCT, 2024 TO 2023 (USD Billion)
FIGURE 12 JAPAN OPHTHALMIC DRUGS AND DEVICES MARKET, BY TREATMENT, 2024 (% SHARE)
FIGURE 13 JAPAN OPHTHALMIC DRUGS AND DEVICES MARKET, BY TREATMENT, 2024 TO 2023 (USD Billion)
FIGURE 14 BENCHMARKING OF MAJOR COMPETITORS

LIST OF TABLES
LIST OF ASSUMPTIONS
JAPAN OPHTHALMIC DRUGS AND DEVICES MARKET SIZE ESTIMATES; FORECAST
TABLE 1 BY PRODUCT, 2026-2023 (USD Billion)
TABLE 2 BY TREATMENT, 2026-2023 (USD Billion)
PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
ACQUISITION/PARTNERSHIP